POINT Biopharma Global Inc

POINT Biopharma Global — SPAC Merger (March 2021)

26 slides from POINT Biopharma Global's SPAC merger presentation, Mar 15, 2021

  1. Slide 1: Accelerating Precision Medicine: Company Overview

    BIOPHARMA Accelerating Precision Medicine™ COINT s Company Overview March 2021

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Except as otherwise indicated or unless the context otherwise requires, all references 1n this presentation to "we," "our," "us," "POINT," or the "Company " refer to POINT B1opharma Inc. The information contained in this presentation is submitted on a confidential basis solely for t

  3. Slide 3: Investment highlights

    A team of experts in clinical development and manufacturing Two Phase 3 assets in prostate cancer and neuroendocrine cancers Exciting early-stage pipeline, including targeted alpha therapy Manufacturing infrastructure in place to supply clinical and enable commercialization POINTBiopharma.come

  4. Slide 4: A leadership team of radiopharmaceutical experts

    A leadership team of radiopharmaceutical experts l am\ Dr. Joe McCann, PhD CEO & Co-Founder Former CEO of a leading Radiopharmaceutical Company Ss crpc) Allan Silber Executive Chairman & Co-Founder Recognized leader in pharmaceutical, healthcare services Michael Gottlieb Chief Commercial Officer \=

  5. Slide 5: POINT creates radioligands by combining a radioisotope, a linker, and a ligand

    POINT creates radioligands by combining a radioisotope, a linker, and a ligand ++ Linker PSMA-PET Scan Before Treatment 1 PSMA =Prostate Specific Membrane Antigen Radioisotope (e.g.Lutetium-177 or Actinium-225) l Radioligand (PNT2002) PSMA-PET Scan After 3 177Lu-PSMA Treatments1 POINTBiopharma.com(1

  6. Slide 6: Our pipeline

    Our pipeline Drug pipeline: Lead Isotopes | Discovery Next Milestone 7 Le u Phase 3 top-line PSMA Fh ssi data mid-2023 Neuroendocrine FDA meeting 3Q Tumors (NETs) 2021 Initiate IND- Early-stage Prostate enabling studies in Cancer Lutetium ShEP 77) Platform technologies: PSMA = Prostate Specific Memb

  7. Slide 7: Indianapolis facility will incorporate radioisotope and radioligand production

    Indianapolis facility will incorporate radioisotope and radioligand production POINTBiopharma.com State of the art 80,000 ft2 GMP facility Modular capacity, capable of scaling with demand Integrated radioisotope production Located near logistic hubs (FedEx HazMat hub and O'Hare Airport) On track for

  8. Slide 8: 177Lu-PNT2002: PSMA targeting ligand for mCRPC

    EDINT BIOPHARMA Accelerating Precision Medicine™ 177Lu-PNT2002: PSMA targeting ligand for mCRPC

  9. Slide 9: Prostate cancer new cases and deaths

    250,000 •200,000 •150,000 •100,000 New CasesDeaths 50,000 Prostate Lung & Bronchus • • Colon & RectumBladderMelanoma (Skin)

  10. Slide 10: Published Phase clinical trial data PNT2002

    Published Phase 2 clinical trial data PNT20021 Sample Size56 Patients Data representative of Standard of Care in upcoming Phase 3 Patients with >50% PSA decline 58.9% ARAT control arm benchmarks rPFS5 (median) Median Progression Free Survival Median Overall Survival 13.7 months (Radiographic) Not re

  11. Slide 11: PNT2002 mCRPC Phase 3 Study Design - SPLASH

    PNT2002 mCRPC Phase 3 Study Design - A splash Protocol’ CLINICAL TRIAL Key Eligibility Criteria: Study Details: Endpoints: * Single arm 25 patient dosimetry lead-in * Two arm 390 patient 2:1 randomization Primary: rPFS by central mCRPC, ECOG 0 to 1 review PSMA-avid PET Progressed on ARAT Randomized

  12. Slide 12: 177Lu-PNT2003: SSTR targeting ligand for Neuroendocrine cancer

    EDINT BIOPHARMA Accelerating Precision Medicine™ 177Lu-PNT2003: SSTR targeting ligand for Neuroendocrine cancer

  13. Slide 13: • • • Dasari A, et al., JAMA Oncol. 2017;3(10):1335-1342.

    • • • Dasari A, et al., JAMA Oncol. 2017;3(10):1335-1342.

  14. Slide 14: PNT2003 trial design

    Design:Sites:Population: Open-label, single arm Phase 3 study (N = 167) Dosing:Customized dose based on dosimetry: 200 mCi (7.4 GBq) initial dose, doses 2 to 4 are adjusted up to 300 mCi or below 200 mCi based on dosimetry results Endpoints:Primary: PFS at 12 months Secondary: Tumor Response, bioche

  15. Slide 15: PNT2003 interim data versus Lutathera and everolimus

    PNT2003 GEP-NETs N=134 PFS@ 12 months*90.9% mPFS33.3 mo6 ORR per RECIST 1.119% Lutathera1,7 GEP-NETs N=116 81.2% Not reached (up to 29 moJ 13% PNT2003 Non GEP-NETs N=33 83.6% mo6 24% Everolimus2,3A,5,7 Non GEP-NETS N= 7-90 14-54% 3.8-13.6 mo 0-9% *Primary endpoint exceeds pre-specified success thres

  16. Slide 16: PNT2001: Next-generation PSMA targeting ligand

    BIOPHARMA ; . Accelerating Precision Medicine™ PNT2001: Next-generation PSMA targeting ligand

  17. Slide 17: Non-metastatic and metastatic castration sensitive market opportunity

    Patients in this space live up to 15 years1, and therefore are at higherrisk of latent radiation toxicity Reducing the risk of long-term latent radiation toxicity would enable PSMA targeted agents to be used earlier Unmet need for drugs that delay the need for lifelong ADT and extend life Non-metast

  18. Slide 18: PNT2001 is a next-generation PSMA radioligand

    PNT2001 is a next-generationPSMAradioligand suited for deliveryof 225Acand 177Lu radioisotopes PNT2001 Preclinical Results: 177Lu SPECT Imaging confirmed similar distribution to other PSMA compounds 1 177Lu Dosimetry found the dose delivered to the tumor was greater when compared to PNT2002 in a sta

  19. Slide 19: PNT2004: Fibroblast Activation Protein-a targeted radioligand

    BIOPHARMA Accelerating Precision Medicine™ POINT <. PNT2004: Fibroblast > Activation Protein-a targeted radioligand |

  20. Slide 20: Targeting Fibroblast Activation Protein-a represents a high value pan-cancer opportunity

    Targeting Fibroblast Activation Protein-a represents a high value pan-cancer opportunity’ FAP-a is an membrane bound enzyme only expressed in tumors but is absent or very low in normal adult tissue? FAP PET imaging supports pan-cancer expression:? (1) Calais, |. Nucl Med 2020 (2) Lindner, T, et al.

  21. Slide 21: 4000 Tumor Volume (mm3) Percent survival 200050 1000 204060 Days Post Treatment Start 0

    4000 100 Tumor Volume (mm3) Percent survival 200050 1000 0 0204060 Days Post Treatment Start 0 01020304050 Days Post Treatment Start

  22. Slide 22: Tumor Microenvironment Targeting Technology

    EDINT BIOPHARMA Accelerating Precision Medicine™ Tumor Microenvironment Targeting Technology

  23. Slide 23: Radiopharmaceuticals could be made TME Activated

    Radiopharmaceuticals could be made TME Activated with our tumor microenvironment targeting technology An early-stage FAP-a activated prodrug technology that attempts to limit a ligand’s ability to bind with receptors on healthy cells, to prevent off-target delivery and improve therapeutic index PNT2

  24. Slide 24: Upcoming Catalysts

    EDINT BIOPHARMA Accelerating Precision Medicine™ Upcoming Catalysts

  25. Slide 25: Anticipated Timelines

    Anticipated Timelines PNT2002 (Prostate Cancer) PNT2003 (SSRT+ non-GEP NETs) PNT2001 (nmCSPC) PNT2004 (Pan-cancer) 202120222023 Dosimet ry • Indianapolis Commissionin Continue production of clinical programs Pre aration for commercial roduction

  26. Slide 26: Transaction sources and uses

    RACA trust equity(2) $135,700 Proceeds from PIPE financing$165,000 Estimated cash contributed from balance sheet$16,000 Equity consideration to existing POINT shareholders$585,000 Tota l sources of funds$901,700 RACA sponsor (RA) - PIPE shares Equity issued to existing POINT shareholders $585,000 Es

POINT Biopharma — SPAC Merger (March 2021) on 6ix